|
Back to Home » December 2018 News » BerGenBio Presents Key Results From PhII Programme With Selective AXL Inhibitor Bemcentinib at DNB's 9th Annual Nordic Healthcare Conference |
BerGenBio Presents Key Results From PhII Programme With Selective AXL Inhibitor Bemcentinib at DNB's 9th Annual Nordic Healthcare Conference |
December 12, 2018
- Bemcentinib proof of concept clinical data as monotherapy and in combination confirms focus on lung cancer & leukaemia - AXL biomarker correlation supports bemcentinib's proposed MoA, potential for Companion Diagnostic - Significant milestones expected over next 12 months BERGEN,...
Source URL: https://www.prnewswire.com:443/news-releases/bergenbio-presents-key-results-from-phii-programme-with-selective-axl-inhibitor-bemcentinib-at-dnb-s-9th-annual-nordic-healthcare-conference-884107479.html
|
|
|
|
